UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism

Endocrinology and metabolism clinics of North America, 2014-03, Vol.43 (1), p.75-102

2014

Volltextzugriff (PDF)

Patient-Reported Outcomes in Endocrinology

Endocrinology and metabolism clinics of North America, 2022-12, Vol.51 (4), p.xv-xvi

Geer, Eliza B.

2022

Volltextzugriff (PDF)

Medical therapy for refractory pituitary adenomas

Pituitary, 2023-06, Vol.26 (3), p.303-306

Geer, Eliza B.

2023

Volltextzugriff (PDF)

Refractory pituitary adenomas: preface

Pituitary, 2023-06, Vol.26 (3), p.261-262

Geer, Eliza B.

2023

Volltextzugriff (PDF)

Predictors of Mortality and Long-term Outcomes in Treated Cushing's Disease: A Study of 346 Patients

The journal of clinical endocrinology and metabolism, 2013-03, Vol.98 (3), p.1022-1030

2013

Volltextzugriff (PDF)

Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab

The journal of clinical endocrinology and metabolism, 2018-10, Vol.103 (10), p.3925-3930

2018

Volltextzugriff (PDF)

Gender differences in insulin resistance, body composition, and energy balance

Gender medicine, 2009, Vol.6 (Suppl 1), p.60-75

2009

Volltextzugriff (PDF)

Mortality in Patients with Endogenous Cushing’s Syndrome

Endocrinology and metabolism clinics of North America, 2018-06, Vol.47 (2), p.313-333

2018

Volltextzugriff (PDF)

Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study

Endocrine, 2017-01, Vol.55 (1), p.247-255

2017

Volltextzugriff (PDF)

Consensus on diagnosis and management of Cushing's disease: a guideline update

The lancet. Diabetes & endocrinology, 2021-12, Vol.9 (12), p.847-875

2021

Volltextzugriff (PDF)

Evaluating Patient-Reported Outcomes in Cushing’s Syndrome

Endocrinology and metabolism clinics of North America, 2022-12, Vol.51 (4), p.691-707

2022

Volltextzugriff (PDF)

Response to Letter to the Editor from Lasolle and Raverot: “USP8 and TP53 Drivers Are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors”

The journal of clinical endocrinology and metabolism, 2021-08, Vol.106 (8), p.e3293-e3294

2021

Volltextzugriff (PDF)

Pituitary surgery is becoming more common: does this reflect a change in tumor incidence, detection, or treatment pattern?

Endocrine, 2018-09, Vol.61 (3), p.355-356

Geer, Eliza B.

2018

Volltextzugriff (PDF)

Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial

The lancet. Diabetes & endocrinology, 2019-11, Vol.7 (11), p.855-865

2019

Volltextzugriff (PDF)

Patients with hypercortisolemic Cushing disease possess a distinct class of hematopoietic progenitor cells leading to erythrocytosis

Haematologica (Roma), 2023-04, Vol.108 (4), p.1053-1067

2023

Volltextzugriff (PDF)

Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies

Breast cancer research and treatment, 2019-02, Vol.174 (1), p.15-26

2019

Volltextzugriff (PDF)

A medical chart audit to assess endocrinologist perceptions of the burden of endogenous Cushing’s syndrome

Pituitary, 2024-04, Vol.27 (2), p.129-140

2024

Volltextzugriff (PDF)

Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma

Pituitary, 2023-08, Vol.26 (4), p.482-487

2023

Volltextzugriff (PDF)

Safety of 5[alpha]-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies

Breast cancer research and treatment, 2019-02, Vol.174 (1), p.15

2019

Volltextzugriff (PDF)

Active Cushing Disease Is Characterized by Increased Adipose Tissue Macrophage Presence

The journal of clinical endocrinology and metabolism, 2019-06, Vol.104 (6), p.2453-2461

2019

Volltextzugriff (PDF)

Body Composition and Cardiovascular Risk Markers after Remission of Cushing's Disease: A Prospective Study Using Whole-Body MRI

The journal of clinical endocrinology and metabolism, 2012-05, Vol.97 (5), p.1702-1711

2012

Volltextzugriff (PDF)

USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors

The journal of clinical endocrinology and metabolism, 2021-03, Vol.106 (3), p.826-842

2021

Volltextzugriff (PDF)

Different patient versus provider perspectives on living with Cushing’s disease

Pituitary, 2024-04, Vol.27 (2), p.141-150

2024

Volltextzugriff (PDF)

Evaluating the burden of endogenous Cushing’s syndrome using a web-based questionnaire and validated patient-reported outcome measures

Pituitary, 2023-08, Vol.26 (4), p.364-374

2023

Volltextzugriff (PDF)

The treatment of aggressive prolactinomas with everolimus

Pituitary, 2023-08, Vol.26 (4), p.474-481

2023

Volltextzugriff (PDF)

1 – 25 von 137

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(115)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(137)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism

Patient-Reported Outcomes in Endocrinology

Medical therapy for refractory pituitary adenomas

Refractory pituitary adenomas: preface

Predictors of Mortality and Long-term Outcomes in Treated Cushing's Disease: A Study of 346 Patients

Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab

Gender differences in insulin resistance, body composition, and energy balance

Mortality in Patients with Endogenous Cushing’s Syndrome

Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study

Consensus on diagnosis and management of Cushing's disease: a guideline update

Evaluating Patient-Reported Outcomes in Cushing’s Syndrome

Response to Letter to the Editor from Lasolle and Raverot: “USP8 and TP53 Drivers Are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors”

Pituitary surgery is becoming more common: does this reflect a change in tumor incidence, detection, or treatment pattern?

Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial

Patients with hypercortisolemic Cushing disease possess a distinct class of hematopoietic progenitor cells leading to erythrocytosis

Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies

A medical chart audit to assess endocrinologist perceptions of the burden of endogenous Cushing’s syndrome

Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma

Safety of 5[alpha]-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies

Active Cushing Disease Is Characterized by Increased Adipose Tissue Macrophage Presence

Body Composition and Cardiovascular Risk Markers after Remission of Cushing's Disease: A Prospective Study Using Whole-Body MRI

USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors

Different patient versus provider perspectives on living with Cushing’s disease

Evaluating the burden of endogenous Cushing’s syndrome using a web-based questionnaire and validated patient-reported outcome measures

The treatment of aggressive prolactinomas with everolimus

Suchergebnisse filtern